| Species |
Human |
| Protein Construction |
GHR/Growth Hormone R (Ala27-Tyr264)
Accession # P10912-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
28.8 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 45-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Pegvisomant, a growth hormone receptor (GHR) antagonist, is a well-known drug that was designed to treat acromegaly. However, recent studies have indicated that the GHR is a 'moonlighting' protein that may exhibit dual functions based on its localization in the plasma membrane and nucleus. |
| Synonyms |
GH receptor; GHBP; GHR; GHR/BP |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
